Humacyte, Inc.

HUMA Nasdaq CIK: 0001818382

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM, NC, 27713
Mailing Address 2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM, NC, 27713
Phone 919-313-9633
Fiscal Year End 1231
EIN 851763759

Financial Overview

FY2025

$137.87M
Total Assets

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 27, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment March 24, 2026 View on SEC
8-K Current report of material events March 19, 2026 View on SEC
8-K Current report of material events March 19, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment January 9, 2026 View on SEC
8-K Current report of material events December 16, 2025 View on SEC
424B5 Prospectus supplement December 16, 2025 View on SEC
8-K Current report of material events December 15, 2025 View on SEC
8-K Current report of material events December 15, 2025 View on SEC
4 Insider stock transaction report December 8, 2025 View on SEC

Annual Reports

10-K March 27, 2026
  • Successful commercial launch of Symvess® for vascular trauma in 2025.
  • Transitioned from a research-focused firm to a commercial-stage company.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.